<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03466463</url>
  </required_header>
  <id_info>
    <org_study_id>GNT-012-CRIG</org_study_id>
    <nct_id>NCT03466463</nct_id>
  </id_info>
  <brief_title>Gene Therapy for Severe Crigler Najjar Syndrome</brief_title>
  <acronym>CareCN</acronym>
  <official_title>A Phase I/II, Open Label, Escalating Dose Study to Evaluate Safety and Efficacy of an Intravenous Injection of GNT0003 (AAV Vector Expressing the UGT1A1 Transgene) in Patients With Severe Crigler-Najjar Syndrome Requiring Phototherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genethon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genethon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1/2, multinational, open-label, escalating-dose study to evaluate the safety
      and efficacy of an intravenous infusion of GNT0003 in patients with Crigler-Najjar aged ≥10
      years and requiring phototherapy. Patients will received a single administration of GNT0003
      and will be followed for safety and efficacy of approximately 60 months (5 years):

        -  a follow-up of approximately 12 months (48 weeks)

        -  a long term follow-up of approximately 48 months (4 years), in order to be in line with
           the latest EMEA Guideline on follow-up of patients administered with gene therapy
           medicinal products, released on 22 Oct.2009 by the Committee for medicinal products for
           human use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">April 27, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events / Serious Adverse Events (Safety) : All Treatment Emergent Adverse Events, all Serious Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of AE/SAE evaluated by changes in laboratory parameters, vital signs, physical examination, reported from baseline to each visit, evaluated for each dose and for the study as a whole. Clinically relevant abnormal findings on Laboratory values, Vital Signs, Physical findings will be reported as Adverse Events.
Incidence and Severity of Adverse Events for each body system will be presented for each dose level and summarized overall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease of total Serum bilirubin level after interruption of daily phototherapy (Efficacy)</measure>
    <time_frame>4 months</time_frame>
    <description>Serum total bilirubin ≤ 300 µmol/L, 7 days after interruption of daily phototherapy occuring at week 16 after the administration of GNT0003.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>60 months</time_frame>
    <description>- Scale 36-Item Short Form Survey (SF-36 Health Survey for adults). Outcome measure: change of quality of life from Baseline to Week 24, Week 48 and yearly up to 48 months after IMP administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment</measure>
    <time_frame>60 months</time_frame>
    <description>- Scale 10-Item Short Form Survey (SF-10 Health Survey for children). Outcome measure: change of quality of life from Baseline to Week 24, Week 48 and yearly up to 48 months after IMP administration.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Crigler-Najjar Syndrome</condition>
  <arm_group>
    <arm_group_label>GNT0003</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 doses of the IMP assessed in a dose escalation, open-label, phase 1/2 study</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>GNT0003</intervention_name>
    <description>Intravenous infusion, single dose</description>
    <arm_group_label>GNT0003</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with severe Crigler-Najjar syndrome resulting from a molecular confirmation
             of mutations in the UGT1A1 gene and requiring phototherapy

          -  Male or female at least 9 years at the date of signature of informed consent

          -  Patient able to give informed assent and/or consent in writing

        Exclusion Criteria:

          -  Patients who underwent liver transplantation

          -  Patients with chronic hepatitis B or C

          -  Patients infected with Human immunodeficiency virus (HIV)

          -  Patients with significant underlying liver disease

          -  Patients with significant encephalopathy

          -  Participation in any other investigational trial during this trial

          -  Patients unable or unwilling to comply with the protocol requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>LABRUNE Philippe, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital Antoine Beclere</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Genethon Clinical Development Department</last_name>
    <phone>00 33 (0)1 69 47 10 32</phone>
    <email>clinical_development@genethon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hopital Antoine BECLERE</name>
      <address>
        <city>Clamart</city>
        <zip>92141</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00 33 (0)1 45 37 42 72</phone>
      <email>philippe.labrune@abc.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe LABRUNE, MD,PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ASST Papa Giovanni XXIII</name>
      <address>
        <city>Bergame</city>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390352674959</phone>
      <email>ldantiga@asst-pg23.it</email>
    </contact>
    <investigator>
      <last_name>Lorenzo D'Antiga, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>00390816132361</phone>
      <email>brunetti@tigem.it</email>
    </contact>
    <investigator>
      <last_name>Nicola Brunetti-Pierri, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AMC</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>0031-641476782</phone>
      <email>u.h.beuers@amc.uva.nl</email>
    </contact>
    <investigator>
      <last_name>Ulrich Beuers, MD, PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2018</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Crigler-Najjar</keyword>
  <keyword>Adeno Associated Virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Crigler-Najjar Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

